Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether somatostatin is more effective that octreotide in the prevention of post-pancreatectomy pancreatic fistula

Clinical Trial Description

Prevention of pancreatic fistula remains a major challenge for surgeons, and various technical and pharmacological intervention have been investigated, with conflicting results. Despite several prospective studies, and metaanalyses, the prophylactic role on pancreatic fistula of octreotide, remains controversial, even if recommended for routine use in patients undergoing pancreatic resection. In view of recent result, the investigators can hypothesize that higher affinity for somatostatin-receptor lead to stronger pancreatic exocrine secretion inhibition, and better pancreatic fistula prevention. Consequently, continuous intravenous infusion of somatostatin-14, the natural peptide hormone, associated with 10 to 50 time stronger affinity with all somatostatin receptor, will be associated with a improved pancreatic fistula prevention compared to octreotide. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03000946
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Status Completed
Phase Phase 3
Start date May 15, 2017
Completion date February 9, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03462602 - Nasogastric Tube in Pancreatic Surgery N/A
Completed NCT04196816 - Surgery for Pancreatic Cancer With Oligo-Metastasis
Completed NCT03791346 - Pancreatectomy for NET: External Evaluation of WHO 2017 Grading System
Completed NCT01059097 - Effect of Surgeon Volume on Outcome of Pancreaticoduodenectomy N/A
Withdrawn NCT00671463 - Pancreatic Stent to Prevent Leak After Distal Pancreatectomy N/A